Momentum is worsening: MACD histogram is negative (-0.00566) and expanding lower, suggesting the selloff is still strengthening.
RSI_6 at 8.477 signals extremely oversold conditions, which can spark sharp dead-cat bounces—but oversold alone is not a buy trigger here.
Key levels: Pivot 0.487 (well above current price 0.3976). Nearby support S1 0.412 (already below), next support S2 0.366. Resistance levels to reclaim: 0.487 then 0.561.
Statistical pattern read-through (similar candlesticks): only modest expected upside (+0.56% next day, +2.97% next week, +4.5% next month), not strong enough to offset the dominant downtrend.
Positioning leans bullish via open interest: Put/Call OI ratio = 0.14 (call-heavy), but this can also reflect speculative lottery-call activity in a penny stock.
Options activity is extremely thin (today’s total volume ~1 contract), so “sentiment” from volume is not reliable.
Volatility is extreme: 30D IV ~391% (IV percentile ~96%), indicating the market is pricing very large moves; this is typically unfavorable for straightforward long entries unless you have a strong edge/timing.
Today vs open interest avg is elevated (51.52), but with such tiny absolute volume, the signal quality remains low.
Technical Summary
Sell
9
Buy
5
Positive Catalysts
can produce a sharp short-term rebound if selling pressure eases.
can act as a catalyst if results surprise positively.
Neutral/Negative Catalysts
can trigger large gaps in either direction.
Financial Performance
Latest quarter provided: 2025/Q4.
Revenue: $138.142M, up 5.92% YoY (top-line growth positive).
Net income: -$8.552M (loss), down -54.73% YoY (losses worsened vs prior year period).
EPS: -$0.25, down -65.75% YoY (earnings power weakening).
Gross margin: 13.82%, up 17.42% YoY (margin improvement is a bright spot, but still low and not yet translating into profitability).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Lake Street (2025-12-04): Maintains Buy rating but cut price target to $3 from $5, citing conservatively revised estimates despite improving foundation.
Wall Street pro view (pros): belief that refinancing + fewer headwinds could allow appreciation if fundamentals improve.
Wall Street con view (cons): target cut signals reduced confidence in near-term trajectory; current price action and worsening earnings metrics support the market’s skepticism.
Wall Street analysts forecast NOTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NOTV is 3 USD with a low forecast of 3 USD and a high forecast of 3 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast NOTV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NOTV is 3 USD with a low forecast of 3 USD and a high forecast of 3 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.390
Low
3
Averages
3
High
3
Current: 0.390
Low
3
Averages
3
High
3
Lake Street
Frank Takkinen
Buy
downgrade
$5 -> $3
AI Analysis
2025-12-04
Reason
Lake Street
Frank Takkinen
Price Target
$5 -> $3
AI Analysis
2025-12-04
downgrade
Buy
Reason
Lake Street analyst Frank Takkinen lowered the firm's price target on Inotiv to $3 from $5 and keeps a Buy rating on the shares. The firm, which thinks the "foundation is improving" and believes a refinancing, coupled with fewer headwinds, will allow shares to appreciate on "a realization of improved fundamentals," is lowering its target to account for its "conservatively revised estimates."
Lake Street
Frank Takkinen
Buy
downgrade
$6 -> $5
2025-05-08
Reason
Lake Street
Frank Takkinen
Price Target
$6 -> $5
2025-05-08
downgrade
Buy
Reason
Lake Street analyst Frank Takkinen lowered the firm's price target on Inotiv to $5 from $6 and keeps a Buy rating on the shares. Inotiv's recovery "continues to trend favorably," but the firm is taking a more conservative stance with its revenue and EBITDA estimates as it now believes its prior view of the recovery ramp was "too steep," the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for NOTV